Unknown PHASE2/PHASE3 INTERVENTIONAL NCT00093301

Levosimendan Versus Dobutamine in Shock Patients

Efficacy of Levosimendan in the Critically Ill Patients With Unstable Hemodynamics (the LICI Study) - A Double Blind Randomized Pilot Study

Sponsor: Abbott

Conditions Cardiogenic Shock Septic Shock

Interventions Dobutamine Levosimendan

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Oct 31, 2004 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Cardiogenic Shock and Septic Shock, this trial is ongoing. The trial is conducted by Abbott and has accumulated 5 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Abbott
Wentworth Area Health Services

Data source: Wentworth Area Health Services

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Penrith, Australia